Zymeworks intends to commence the Share Repurchase Program with 140.0 million in share repurchases expected through 2028, with flexibility to adjust the pace of repurchases based on market opportunities, cash flow, and e
Why Is Zymeworks Inc. (ZYME) Stock Down Today?
Updated Nov 17, 2026 6:30 PM ET · Prev Close $26.45
Primary Move Catalyst & Conviction
65% Signal ConvictionPharmaceuticals & Therapeutics sector moving together
This appears to be a sector-wide move. The Pharmaceuticals & Therapeutics sector is down 1.9% on average.
Market & Sector Relative Strength
ZYME lagging the S&P 500 by -0.68%Options Flow & Execution Desk
Neutral Flow · P/C 1.17Recent ZYME Catalyst Headlines
Verified WireZymeworks reported third quarter 2026 revenue of US 256.46 million and net income of US 173.7 million, with earnings supported by a large milestone payment from Jazz Pharmaceuticals tied to Ziihera s FDA approval. The up
Zymeworks ZYME delivered earnings and revenue surprises of -5.00 and 2.72 , respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zymeworks CEO Kenneth Galbraith speaks about the company s progress for in Q3 2026 2026 financial guidance raised to a total revenue range of 337 million to 351 million previously between 278 million and 292 million and
1–3 Day Expected Range & Key Level
45% Follow-ThroughWatch for breakdown below $25.76
Technical Regime (ZYME)
MIXED MA TREND1-Year Historical Move Analogs
32 EventsSessions in the past year where ZYME moved >3.0% down:
Retail & Crowd Sentiment
Very BullishZymeworks announced a new $200 million share repurchase program, intending to spend approximately $140.0 million through 2028.
About Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentia...
Get Instant ZYME Catalyst Alerts
Receive an email alert when ZYME triggers an unusual volume breakout, options sweep, or rating shift.
Other Liquid Stocks Moving Today
All Today's MoversZYME Session & Catalyst FAQ
Why is ZYME stock down today?
This appears to be a sector-wide move. The Pharmaceuticals & Therapeutics sector is down 1.9% on average.
Is ZYME stock a buy or sell right now?
Today's session carries a 65% catalyst conviction score on 0.12x relative volume (low participation). Our multi-factor model currently rates ZYME as HOLD. Review full valuation, quality, and timing signals on the ZYME Buy or Sell Decision Brief →
What is ZYME's intrinsic value and expected trading range?
At $26.03, ZYME's modeled 1-to-3 session range is $24.99 – $26.28, with a key inflection level at $24.47 (support). Compare current price against multi-year cash flow projections in the ZYME Intrinsic Value & DCF Model → and Market Cycle Phase Tracker →
What do RSI and moving averages signal for ZYME?
RSI at 40.6 reflects soft below-midline momentum. ZYME trades at $26.03 relative to its 20-day SMA ($28.64) and 50-day SMA ($27.22), reflecting a mixed moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.